Neuro

Results from BRAIN.Q’s EMAGINE Study on the Use of AI-Powered Electromagnetic Field Therapy Offer Hope for Meaningful Recovery Following Stroke

Promising results from the EMAGINE randomized trial suggest that treatment with BRAIN.Q’s AI-powered low electromagnetic field stimulation, aimed at enhancing the brain’s ability to relearn processes lost after a stroke, may help patients regain ‘freedom from disability’ with greater…

ACTICOR BIOTECH: Presentation of the Main Results of the Phase 2/3 ACTISAVE Study in the Treatment of Stroke at ESOC 2024

PARIS–(BUSINESS WIRE)–Regulatory News: “ACTISAVE Clinical Trial: Efficacy and Safety of Glenzocimab on Top of Thrombolysis with or without Mechanical Thrombectomy.” Post this ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, […]

Viz.ai and NICO Corporation Announce Collaboration to Improve Outcomes in Patients with Intracerebral Hemorrhage

SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with NICO Corporation (NICO), a leader in modern minimally-invasive interventional technologies for neurosurgery, to improve the lives of patients with intracerebral hemorrhages. “We’re excited to collaborate with NICO, leveraging our broadly deployed AI […]

SyntheticMR and SimonMed Expand Trials of Synthetic MRI Testing and Announce Upcoming Expansion of Synthetic Availability from SyntheticMR’s SyMRI NEURO Software at SimonMed Facilities

LINKÖPING, Sweden, April 17, 2024 /PRNewswire/ — SimonMed Imaging (“SimonMed”), one of the largest outpatient medical imaging providers and radiology practices in the United States, announces the continuation of its partnership with SyntheticMR for research as well as the upcoming…